BruhCormedix and Acasti got my portfolio on swole this week
The Official CORMEDIX (CRMD)thread (run up to FDA approval has begun )
- Thread starter Tug life
- Start date
ahomeplateslugger
Superstar
nice gains lately for CRMD, ACST and MTNB. AMRN seems to be rebounding. i think it shook off all the shorts and will start to climb now. there's no other reason for it to drop other than ppl shorting or selling and taking profits. the books all look good. hopefully it gaps up from here. would be nice to have all 4 stocks double, triple or grow 4x. i bought a little more ACST when it was at 2.05 and glad i got in before it took off
Last edited:
Tug life
I stay fly like a guillemot
If you are nervous about Acasti's data now would be a perfect time to take profits or close the position. SSR (short seller restriction) rules are in play today so that means short sellers can't sell into the bid. That's why we aren't seeing large drops.
This is where emotions come into play for me because with an average at $1.92 I could ride off into the sunset with around 40% profit. But I'm holding until data and data release and I'll sell 1/3 of my shares and buy back in after the spike.
This is where emotions come into play for me because with an average at $1.92 I could ride off into the sunset with around 40% profit. But I'm holding until data and data release and I'll sell 1/3 of my shares and buy back in after the spike.
Watched the whole video and did a little DD. This type of tech is undoubtedly the way if the future especially when 5G and the internet of things (IOT) fully get rolled out. I really like the different products they have and I can see it being used in a everyday setting especially the chat and ad features.
They always say if you want to know how good a companies product is you should just try it. I tried to use the feature on vacuumcleanermarket.com but my phones graphics card is too shytty
I gotta find a brokerage that allows investing in otc stocks because my current ones don't allow it otherwise I would invest in this. It is very similar to Wimi Hologram cloud the Chinese company that had a Wework type IPO. I was hype about that but with Nextech being a North American player I can rock with this
Yahoo is now part of Verizon Media
Nextech and FB messenger.
Tug life
I stay fly like a guillemot
holy shyt this is huge. I didn't get in yet hopefully by the time I get access to the otc markets it'll be a good priceIcosapent ethyl may act on plaque
Although the primary outcome was not met at 9 months, several secondary outcomes were significant, including a 57% reduction in fibrous plaque progression, an 89% reduction in calcified plaque progression, a 19% reduction in total noncalcified plaque progression and a 42% reduction in total plaque progression (Table). Total plaque volume increased by 20 mm3 in the EPA group and by 34 mm3 in the placebo group. Fibrofatty plaque progression increased in the icosapent ethyl group, although this result was not statistically significant (P = .65).
Good read on the Evap trail and Vascepa overall.
Still stings a bit that Dr. Budoff admitted he chose the wrong outcome for this trail. If he chose calcified plaque, this trail would have been halted and Amarin would be drafting up another sNDA for the FDA.
Heres the end of the article:
Although the primary outcome of the EVAPORATE trial was not met at this initial time point, the trial will continue for 18 months before reporting final results. In the meantime, the reduction in overall plaque progression helps clarify a possible mechanism by which icosapent ethyl reduces CV events. Due to its lipophilic nature, EPA can become incorporated into atherosclerotic plaques, and may play a role increasing plaque stability. Perhaps by stabilizing plaque and slowing overall atherosclerotic progression, this is a mechanism by which high-dose EPA is able to exert part of the CV benefit.
These preliminary results are encouraging in elucidating the cardioprotective role of high-dose EPA and will need further confirmation. We look forward to seeing the 18-month CTA results of this innovative study.
Although the primary outcome was not met at 9 months, several secondary outcomes were significant, including a 57% reduction in fibrous plaque progression, an 89% reduction in calcified plaque progression, a 19% reduction in total noncalcified plaque progression and a 42% reduction in total plaque progression (Table). Total plaque volume increased by 20 mm3 in the EPA group and by 34 mm3 in the placebo group. Fibrofatty plaque progression increased in the icosapent ethyl group, although this result was not statistically significant (P = .65).
Good read on the Evap trail and Vascepa overall.
Still stings a bit that Dr. Budoff admitted he chose the wrong outcome for this trail. If he chose calcified plaque, this trail would have been halted and Amarin would be drafting up another sNDA for the FDA.
Heres the end of the article:
Although the primary outcome of the EVAPORATE trial was not met at this initial time point, the trial will continue for 18 months before reporting final results. In the meantime, the reduction in overall plaque progression helps clarify a possible mechanism by which icosapent ethyl reduces CV events. Due to its lipophilic nature, EPA can become incorporated into atherosclerotic plaques, and may play a role increasing plaque stability. Perhaps by stabilizing plaque and slowing overall atherosclerotic progression, this is a mechanism by which high-dose EPA is able to exert part of the CV benefit.
These preliminary results are encouraging in elucidating the cardioprotective role of high-dose EPA and will need further confirmation. We look forward to seeing the 18-month CTA results of this innovative study.
anyone heard of pavm.. supposedly they make medical devices.. ,might be a good stock.. i dumped some money into it a few weeks ago
PAVM PAVmed Inc — Stock Price and Discussion | Stocktwits
PAVM PAVmed Inc — Stock Price and Discussion | Stocktwits
interesting. wanna hit at least 2K shares of Nextech b4 I add anything else tho.
***From YMB
Upcoming catalysts (courtesy a couple bulls there):
1. They just commercially launched a first ever esophageal cancer screening test that will address an estimated billion dollar market (will see revenue in Q1 2020).
2. They just finished the trials for CarpX, a unique and minimum invasive carpel tunnel tool/procedure with patents, and plan to submit to FDA for approval in January (they have been working with FDA since summer on it). This will address a multi billion dollar market, and should see approval sooner than 90 days, at which time they will start training physicians. Profit Q2 2020
3. They are working on finalizing a merger or acquisition deal with their product NexFlo, which will bring in an instant influx of cash
Medium term:
1. Working on a product called DissapEAR, an implantable ear tube for children that disintegrates, eliminating the need for another procedure
Long term:
2. Working on glucose monitor using lasers
And don't forget PortIO, their implantable medicine release product which does not need frequent flushing the way implants do today. Nothing like it in the market. I think this is both a short (they will be applying for approval for a 7 day implant soon) and longer term (starting trials for implant to remain for 6 months) product and could be big also
Tug life
I stay fly like a guillemot
Must read article on Acasti, I'm gonna put the highlights below.
Acasti Pharma – pivotal Phase (3) results moment is upon us - Align Research
Acasti Pharma – pivotal Phase (3) results moment is upon us - Align Research
$ITCI up 115% after FDA approval
ahomeplateslugger
Superstar
ACST just took a big dip
i don't see any news tho. maybe ppl taking profits?
i don't see any news tho. maybe ppl taking profits?